Terms ending in 2026
Every in-force patent on AbbVie Inc.'s record whose computed term ends in 2026, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 7,504,520 | Antagonists of the Vanilloid Receptor Subtype 1 (VR1) and Use Thereof In force · High confidence | AbbVie Inc. | In force | High confidence | |
| US 10,323,084 | Monoclonal Antibodies Against Amyloid Beta Protein and Uses Thereof In force · Medium confidence | AbbVie Deutschland GmbH & Co. KG | In force | Medium confidence | |
| US 10,538,581 | Anti-Ab Globulomer 4D10 Antibodies In force · Medium confidence | AbbVie Deutschland GmbH & Co. KG | In force | Medium confidence | |
| US 7,763,731 | Anti-Viral Compounds In force · High confidence | AbbVie Inc. | In force | High confidence | |
| US 8,338,605 | Anti-Viral Compounds In force · High confidence | AbbVie Inc. | In force | High confidence | |
| US 7,767,684 | Apoptosis Promoters In force · Medium confidence | AbbVie Inc. | In force | Medium confidence | |
| US 8,748,108 | Biomarkers for Identifying Patient Classes In force · High confidence | AbbVie Inc. | In force | High confidence |
7 of 7 patents shown. Soonest term end first, then patent number.
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.